#USA #Chicago #Breast Cancer #Transpara #ScreenPoint Medical

ScreenPoint Medical Unveils New FDA Approval for Transpara

At the 110th annual meeting of the Radiological Society of North America (RSNA) held from December 1 to 4, 2024, in Chicago, ScreenPoint Medical introduced significant advancements for its Transpara system, designed to enhance the early detection of breast cancer. This new FDA authorization showcases innovative features that enable radiologists to assess breast density and use temporal comparison, optimizing workflow and improving clinical diagnostics.

Enhancements in Transpara

The updated version, Transpara 2.1, features enhancements based on extensive training and feedback from a global network of users. One of the standout features is its ability to analyze suspicious areas against data from up to three previous exams over a six-year period. This capability of robust temporal comparison is a unique offering in the market, expected to aid radiologists significantly. Alejandro Rodriguez Ruiz, PhD, highlighted during a presentation at ECR 2024 that the autonomous performance of the Transpara system ranks among the top 10% of radiologists.

Quoting Experts

Professor Nico Karssemeijer, PhD, co-founder and scientific director of ScreenPoint Medical, expressed excitement about Transpara's advancements, stating: "The incorporation of tissue changes for outcome characterization has long been anticipated. The substantial improvements in Transpara's performance, particularly when leveraging previous exams, align with radiologists' real-world experiences. Our solution is purpose-built for screening and diagnostics, enhancing workflow efficiency. The effect of prior examinations is presented to users, promoting confidence and transparency in results."

Clinical Studies Presented

In conjunction with the release of Transpara 2.1, various clinical studies detailing the benefits of Transpara’s technology were shared at the RSNA. For instance, a prospective study titled "Putting It In Perspective: AI Triage Streamlining Screening Mammogram Turnaround Time Amid Staff Shortages" demonstrated how AI software could streamline workflow by prioritizing interpretations based on the Transpara score, leading to significant improvements in turnaround times for breast cancer detection and diagnosis.

Another study, "Implementation Of A Convolutional Neural Network Based Detection Software As An Independent Third Reader In the German Mammography Screening: A Prospective Study," explored the implications of AI-assisted mammography as a third reader within Germany's screening program. It showed that implementing Transpara as a decision support tool increased cancer detection rates, particularly for invasive cancers.

Finally, an evaluation focused on the AI’s capability to assist in detecting cancer in women with dense breast tissue highlighted that studies assessed using Transpara exhibited a strong predictive value for cancer detection across both dense and non-dense breast scenarios.

Proven Track Record

Transpara stands out with over 35 peer-reviewed publications demonstrating its effectiveness in real-world screening populations, including renowned institutions such as UCLA and the Norwegian Cancer Registry. Research indicates that its use can lead to up to 45% earlier detection of interval cancers, while also alleviating radiologist workload and optimizing clinical workflow.

About ScreenPoint Medical

ScreenPoint Medical is at the forefront of translating advanced machine learning research into accessible technology for radiologists, aimed at enhancing breast cancer screening workflows, decision-making confidence, and risk assessment. With continual updates informed by feedback from leading specialists in mammography imaging, Transpara is built on a foundation of trust among radiologists worldwide. All evidence supporting Transpara can be found on their published resources online.

For more detailed information regarding Transpara's impact in clinical settings, visit ScreenPoint Medical.